Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events.
Saved in:
| Title: | Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events. |
|---|---|
| Authors: | Wigle, Theodore J.1 (AUTHOR), Povitz, Brandi L.2 (AUTHOR), Medwid, Samantha1,3 (AUTHOR), Teft, Wendy A.3 (AUTHOR), Legan, Robin M.3 (AUTHOR), Lenehan, John4 (AUTHOR), Nevison, Stephanie5 (AUTHOR), Panuganty, Veera4 (AUTHOR), Keller, Denise6 (AUTHOR), Mailloux, Jaymie1,3 (AUTHOR), Siebring, Victoria6 (AUTHOR), Sarma, Sisira7 (AUTHOR), Choi, Yun‐hee7 (AUTHOR), Welch, Stephen4 (AUTHOR), Winquist, Eric4 (AUTHOR), Schwarz, Ute I.3 (AUTHOR), Kim, Richard B.1,3 (AUTHOR) Richard.Kim@lhsc.on.ca |
| Source: | CTS: Clinical & Translational Science. Jul2021, Vol. 14 Issue 4, p1338-1348. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
